233 related articles for article (PubMed ID: 17460787)
1. Strategies for suppressing angiogenesis in gynecological cancers.
Ma WW; Jimeno A
Drugs Today (Barc); 2007 Apr; 43(4):259-73. PubMed ID: 17460787
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.
Frumovitz M; Sood AK
Gynecol Oncol; 2007 Mar; 104(3):768-78. PubMed ID: 17306693
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis as targeted breast cancer therapy.
Hayes DF; Miller K; Sledge G
Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
[TBL] [Abstract][Full Text] [Related]
5. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
Collins TS; Hurwitz HI
Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507
[TBL] [Abstract][Full Text] [Related]
6. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
Ferrara N
Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis as a strategic target for ovarian cancer therapy.
Spannuth WA; Sood AK; Coleman RL
Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
[TBL] [Abstract][Full Text] [Related]
8. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
9. Current status of signal transduction modulators in the treatment of gynecologic malignancies.
Ashouri S; Garcia AA
Curr Treat Options Oncol; 2007 Dec; 8(6):383-92. PubMed ID: 18196458
[TBL] [Abstract][Full Text] [Related]
10. [Anti-angiogenesis targeting drugs: a review].
Jia K; Li J
Ai Zheng; 2008 Apr; 27(4):442-6. PubMed ID: 18423135
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor as a target for anticancer therapy.
Ferrara N
Oncologist; 2004; 9 Suppl 1():2-10. PubMed ID: 15178810
[TBL] [Abstract][Full Text] [Related]
13. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
14. VEGF as a therapeutic target in cancer.
Ferrara N
Oncology; 2005; 69 Suppl 3():11-6. PubMed ID: 16301831
[TBL] [Abstract][Full Text] [Related]
15. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
Homsi J; Daud AI
Cancer Control; 2007 Jul; 14(3):285-94. PubMed ID: 17615535
[TBL] [Abstract][Full Text] [Related]
17. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
18. The role of angiogenesis inhibitors in prostate cancer.
Aragon-Ching JB; Dahut WL
Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic agents in cancer therapy.
Lenz HJ
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]